umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Bioaccessibility and bioavailability of environmental semi-volatile organic compounds via inhalation: A review of methods and models
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen. Swetox, Karolinska Institute, Unit of Toxicology Sciences, Forskargatan 20, SE-151 36 Södertälje, Sweden.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Environment International, ISSN 0160-4120, E-ISSN 1873-6750, Vol. 113, s. 202-213Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Semi-volatile organic compounds (SVOCs) present in indoor environments are known to cause adverse health effects through multiple routes of exposure. To assess the aggregate exposure, the bioaccessibility and bioavailability of SVOCs need to be determined. In this review, we discussed measurements of the bioaccessibility and bioavailability of SVOCs after inhalation. Published literature related to this issue is available for 2,3,7,8-tetrachlorodibenzo-p-dioxin and a few polycyclic aromatic hydrocarbons, such as benzo[a] pyrene and phenanthrene. Then, we reviewed common modeling approaches for the characterization of the gas-and particle-phase partitioning of SVOCs during inhalation. The models are based on mass transfer mechanisms as well as the structure of the respiratory system, using common computational techniques, such as computational fluid dynamics. However, the existing models are restricted to special conditions and cannot predict SVOC bioaccessibility and bioavailability in the whole respiratory system. The present review notes two main challenges for the estimation of SVOC bioaccessibility and bioavailability via inhalation in humans. First, in vitro and in vivo methods need to be developed and validated for a wide range of SVOCs. The in vitro methods should be validated with in vivo tests to evaluate human exposures to SVOCs in airborne particles. Second, modeling approaches for SVOCs need to consider the whole respiratory system. Alterations of the respiratory cycle period and human biological variability may be considered in future studies.

Ort, förlag, år, upplaga, sidor
Elsevier, 2018. Vol. 113, s. 202-213
Nyckelord [en]
SVOCs, Respiratory tract, Absorption, Deposition, Inhalation exposure, Internal dose
Nationell ämneskategori
Farmaceutiska vetenskaper
Identifikatorer
URN: urn:nbn:se:umu:diva-148651DOI: 10.1016/j.envint.2018.01.024ISI: 000428976700024PubMedID: 29448239Scopus ID: 2-s2.0-85041804415OAI: oai:DiVA.org:umu-148651DiVA, id: diva2:1222489
Tillgänglig från: 2018-06-21 Skapad: 2018-06-21 Senast uppdaterad: 2018-06-21Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Gustafsson, Åsa

Sök vidare i DiVA

Av författaren/redaktören
Gustafsson, ÅsaRamalho, Olivier
Av organisationen
Kemiska institutionen
I samma tidskrift
Environment International
Farmaceutiska vetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 32 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf